Get started
Hoth Therapeutics, Inc.Hoth Therapeutics, Inc.Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

HOTH trade ideas

HOTH Bullish after it Completes Phase 1 Eczema treatment Study===================== HOTH ( Hoth Therapeutics , Inc.) Float: 4.16M Alert Price: $4.1954 Target Price: $8.00 (Diamond Equity Research) Chart Analysis Investor Presentation Website | Recent News ======================== Members, Earlier today we promised you an amazing opportunity trading on the Nasdaq exchange. The Company operates in the highly lucrative biopharmacetical sector, and is making some great strides towards FDA approval. Please turn your immediate attention to HOTH ( Hoth Therapeutics , Inc.) HOTH is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders. On Tuesday, the Company announced that they have completed Phase I of their In-Life dose escalation study. The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. This was just the latest in a long string a milestones for the company. Recent Milestones Successfully completed Phase I of In-Life Dose Escalation Study for Treating Eczema Diamond Equity Research initiated coverage on the Company and slapped on an $8 price target Received positive results from pilot study of BioLexa on Diabetic Skin Ulcers Entered into a definitive partnership agreement with Zylö Therapeutics to develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus , a chronic autoimmune disease that affects the skin. Entered into licensing agreement with the University of Maryland and Isoprene Pharmaceuticals. (March 2019) Began pilot study in chronic diabetic ulcers at Mass General Vaccine and Immunotherapy Center (March 2019) Announced Closing of Initial Public Offering. Here a a few reasons why we believe that HOTH is due for a big move in the near future. Has a tight float of 4.16M Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News) Is listed on the Nasdaq Exchange (High Liquidity) Analysts recently assigned an $8 Price Target, which is an upside of over +90% from today's alert price Successfully completed Phase I of In-Life Dose Escalation Study for Treating Eczema Received positive results from pilot study of BioLexa on Diabetic Skin Ulcers Shortened path towards regulatory approval Multiple near-term catalysts for value creation. Peer group valuations are compelling: Pfizer recently paid $4.9 billion for Anacor (lead product, Eucrisa, is a topical treatment for mild to moderate eczema.) HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88. HOTH's recent pullback has created the ultimate buy the dip opportunity for traders. We all know how explosive these small-cap biotech stocks can be... With HOTH's tiny 4.16M float, any type of market friendly news could send shares soaring. HOTH also has several bullish catalysts on the horizon that have us confident that its $8.00 price-target is well within reach. Atopic Dermatitis is a large and growing market Affects more than 32 million patients in the US 10 20% of all pediatric patients suffer from Atopic Dermatitis Need for new, differentiated therapies HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019 Study will test efficacy, safety, and ease of use On target to complete Phase 2 clinical trial by end of Q1 2020 As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline. Can you imagine how high HOTH shares could go if it were to receive FDA approval? Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains. About HOTH Therapeutics Hoth Therapeutics , Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform. Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur. They intend to explore the use of the BioLexa™ Platform for the treatment of atopic dermatitis, or eczema. They also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. They believe that the BioLexa Platform™s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection. Finally, they intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform™s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus. Genetic Marker License Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology. Company Highlights: Unique small cap specialty pharma investment opportunity with multiple shots on goal and capital business model. Multi-billion market opportunity with large unmet need for both the Company’s primary and secondary asset. Proprietary platform technology which combines two existing approved drugs enabling reliance on existing safety data for those drugs. Proprietary BioLexa platform technology which combines two existing approved drugs enabling reliance on existing safety data. VNLG 152 strong pre-clinical data in acne and psoriasis. Strong IP Portfolio, including licenses to patents and trademarks. Signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin. Experienced management team, board of directors and scientific advisors with proven drug development experience. HOTH Is Moving Closer Towards FDA Approval Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema Last Wednesday, HOTH announced that they have completed Phase I of their In-Life dose escalation study. The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. There were two phases with the first phase of the study being completed in September of 2019. Phase I In-Life Dose Escalation Study Searching for the maximum feasible volume . Initiated at 0.5 ml/kg, and then increased to 1.0 mg/kg, 1.5 mg/kg, and 2.0 mg/ kg once daily approximately every 18-24 hours. Found no visible lesions on any of trial patients. "Management is pleased that our BioLexa Platform continues to demonstrate an impressive safety profile during its testing phase," said, Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics . "We believe this therapeutic candidate has the potential to provide significant benefits to people afflicted by Atopic Dermatitis. Going forward, we are focused on expanding our clinical efforts into later stage trials." This stage of the toxicity study was designed to determine dose-limiting adverse events and to define the maximum tolerated dose of the BioLexa Platform. The BioLexa Platform is a proprietary, patented therapeutic designed for the treatment of atopic dermatitis. Over +90% In Upside Potential From Today's Alert Price Diamond Equity Research Initiates Coverage on Hoth Therapeutics , Inc. Slaps on $8.00 Price Target The full research report is available here. Highlights from the report include: Large Market Opportunity Awareness of skin disorders has grown exponentially in recent decades, driving demand for more effective treatments. Eczema is one of the most prevalent skin diseases, with atopic dermatitis (AD) being the most common type affecting a significant portion of the global population. The National Eczema Association estimates conservatively that 31.6 million individuals in the U.S. suffer from eczema, incurring an annual economic burden of around $5.3 billion. The study anticipates that the AD drug sales in the U.S. will grow to $13.6 billion by 2027, which indicates a significant potential market for effective AD treatments. HOTH’s lead product, BioLexa offers a novel potential therapy to treat AD (eczema). It expects to commence a phase 2 trial with enrollment starting in Australia in the end of 2019, with the company targeting a data readout in 1H 2020. The company expects to file the new drug application from mid- to late 2021, which means HOTH could potentially launch its lead product in the U.S. market in 2023. Although HOTH’s investment and timeline in getting its drugs to market are relatively small compared to traditional drug development, HOTH’s pipeline is still earlier stage. We believe HOTH is well positioned to provide investors a unique, high risk high reward small-cap specialty pharma investment opportunity, with its multiple differentiated potential treatments under development. Unique Atopic Dermatitis Treatment Approach HOTH is an early-clinical-stage biopharmaceutical company developing its lead product BioLexa, a unique potential targeted treatment for mild to moderate atopic dermatitis (AD; also known as eczema). BioLexa is one of the first drug candidates to prevent symptoms triggering eczema rather than simply treating symptoms after they occur. It is differentiated as it combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms; in simpler terms, it targets the bacteria as opposed to other eczema treatments addressing the immune-related and inflammatory factors. Hoth uses approved drugs that would enable it to take the faster 505 (b) (2) route for regulatory approval of BioLexa, if the upcoming clinical studies indicate positive results.The company also working with the George Washington University to counter the dermatological-related side effects of Erlotinib therapy in cancer patients, and is developing VNLG 152 with strong preclinical data in the fields of cancer and dermatology. HOTH has established relationships with renowned doctors and scientists and top medical institutions. It recently signed an exclusive licensing agreement with the University of Cincinnati to obtain a patented new food allergy genetic marker; started a pilot study on diabetic skin disorders with the Massachusetts General Hospital’s Vaccine and Immunology Center; expanded its working relationship and signed an exclusive licensing agreement with George Washington University; and entered into a commercial licensing agreement with the University of Maryland (Baltimore) and Isoprene Pharmaceuticals Inc. We anticipate further licensing agreements and collaborations going forward. Competition The global dermatitis drugs market continues to expand, driven by the advancements in numerous drug classes. The AD therapeutics market currently uses conventional forms of therapy such as topical corticosteroids, calcineurin inhibitors, and PDE4 inhibitors to treat patients with mild to moderate AD symptoms. HOTH expects to face significant competition from other current treatments and the development pipelines of large pharmaceutical companies and emerging biotechnology companies. That said, we believe HOTH is well positioned in the industry, with its (1) novel and differentiated potential treatment targeted at preventing the formation of bacterial biofilm and addressing the potential impairment of skin barrier function, (2) patented BioLexa Platform, which combines two existing approved drugs, enabling reliance on existing safety data for those drugs, which could result in faster regulatory approval, (3) strong intellectual property portfolio, including exclusive licenses to patents and trademarks, and (4) additional potential therapies targeting dermatological issues and genetic disorders, including diabetic ulcers, skin aesthetics, psoriasis, and food allergies. Attractive Valuation It is very difficult to value Hoth Therapeutics , Inc. given its early stage and the limited number of similar publicly traded dermatology companies. In our comparable company analysis , we screened for small-capitalization companies in the biopharmaceutical industry focused on developing therapeutics for eczema. We used a blend of these companies to arrive at a mean technology value. We also built a discounted cash flow to value HOTH . From our blended valuation models, we found the shares to be undervalued with significant upside from current trading levels. Based on an average of the two methods, we computed a blended valuation of $8 per share, indicating the stock is undervalued relative to current prices. Market Outlook: More than $320 billion was spent on prescription drugs in the U.S. in 2016, a figure that's expected to nearly double to $610 billion by 2021, according to IQVIA (formerly QuintilesIMS). With so much money being spent on necessary medicines , there's serious opportunity for pharmaceutical companies and investors alike. Atopic dermatitis market predicted to grow $7.2B in 2017 to $24B by end of 2027. It affects more than 32 million patients in the US. Diabetic Foot Ulcers affect approximately 9.1-26.1M people worldwide, about 19 34% of people with diabetes are likely to be affected. Nearly 7.5 million people are affected by psoriasis in the US alone and represent about 2% of the population with approximately 100,000 new cases reported each year.* 60 million people suffering from all grades of acne in the US, 20% of which is severe enough to result in facial scarring. Technical Analysis As we stated above, with HOTH's tiny 4.16M float, any type of market friendly news could send its shares soaring. HOTH has plenty of room to the upside, a move back to its 52-week high of $13.88 would net traders over +230% in profit from today's alert price. We've done our very own chart analysis, and see the potential for a move of over +18% from here. Bullish divergence is forming. HOTH has established strong support at these levels. We've watch HOTH make several strong bounces off support in the past. The Bottom-Line We love these low-float bio-tech alerts. They have the tendency to breakout faster and bigger than any other sector. HOTH's management team possesses a wealth of experience, and we believe that they are the right group of individuals to get this game-changer in the pharma space on the right path towards FDA approval (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, *Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $20,000 cash for a 2-day marketing contract for HOTH . Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
NASDAQ:HOTHLong
by RedHotStocks
HOTH Successfully Completes Phase 1 Eczema Treatment Study===================== HOTH (Hoth Therapeutics, Inc.) Float: 4.16M Alert Price: $4.1954 Target Price: $8.00 (Diamond Equity Research) Chart Analysis Investor Presentation Website | Recent News ======================== Members, Earlier today we promised you an amazing opportunity trading on the Nasdaq exchange. The Company operates in the highly lucrative biopharmacetical sector, and is making some great strides towards FDA approval. Please turn your immediate attention to HOTH (Hoth Therapeutics, Inc.) HOTH is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders. On Tuesday, the Company announced that they have completed Phase I of their In-Life dose escalation study. The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. This was just the latest in a long string a milestones for the company. Recent Milestones Successfully completed Phase I of In-Life Dose Escalation Study for Treating Eczema Diamond Equity Research initiated coverage on the Company and slapped on an $8 price target Received positive results from pilot study of BioLexa on Diabetic Skin Ulcers Entered into a definitive partnership agreement with Zylö Therapeutics to develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus , a chronic autoimmune disease that affects the skin. Entered into licensing agreement with the University of Maryland and Isoprene Pharmaceuticals. (March 2019) Began pilot study in chronic diabetic ulcers at Mass General Vaccine and Immunotherapy Center (March 2019) Announced Closing of Initial Public Offering. Here a a few reasons why we believe that HOTH is due for a big move in the near future. Has a tight float of 4.16M Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News) Is listed on the Nasdaq Exchange (High Liquidity) Analysts recently assigned an $8 Price Target, which is an upside of over +90% from today's alert price Successfully completed Phase I of In-Life Dose Escalation Study for Treating Eczema Received positive results from pilot study of BioLexa on Diabetic Skin Ulcers Shortened path towards regulatory approval Multiple near-term catalysts for value creation. Peer group valuations are compelling: Pfizer recently paid $4.9 billion for Anacor (lead product, Eucrisa, is a topical treatment for mild to moderate eczema.) HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88. HOTH's recent pullback has created the ultimate buy the dip opportunity for traders. We all know how explosive these small-cap biotech stocks can be... With HOTH's tiny 4.16M float, any type of market friendly news could send shares soaring. HOTH also has several bullish catalysts on the horizon that have us confident that its $8.00 price-target is well within reach. Atopic Dermatitis is a large and growing market Affects more than 32 million patients in the US 10 20% of all pediatric patients suffer from Atopic Dermatitis Need for new, differentiated therapies HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019 Study will test efficacy, safety, and ease of use On target to complete Phase 2 clinical trial by end of Q1 2020 As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline. Can you imagine how high HOTH shares could go if it were to receive FDA approval? Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains. About HOTH Therapeutics Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform. Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur. They intend to explore the use of the BioLexa™ Platform for the treatment of atopic dermatitis, or eczema. They also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. They believe that the BioLexa Platform™s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection. Finally, they intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform™s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus. Genetic Marker License Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology. Company Highlights: Unique small cap specialty pharma investment opportunity with multiple shots on goal and capital business model. Multi-billion market opportunity with large unmet need for both the Company’s primary and secondary asset. Proprietary platform technology which combines two existing approved drugs enabling reliance on existing safety data for those drugs. Proprietary BioLexa platform technology which combines two existing approved drugs enabling reliance on existing safety data. VNLG 152 strong pre-clinical data in acne and psoriasis. Strong IP Portfolio, including licenses to patents and trademarks. Signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin. Experienced management team, board of directors and scientific advisors with proven drug development experience. HOTH Is Moving Closer Towards FDA Approval Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema Last Wednesday, HOTH announced that they have completed Phase I of their In-Life dose escalation study. The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. There were two phases with the first phase of the study being completed in September of 2019. Phase I In-Life Dose Escalation Study Searching for the maximum feasible volume. Initiated at 0.5 ml/kg, and then increased to 1.0 mg/kg, 1.5 mg/kg, and 2.0 mg/ kg once daily approximately every 18-24 hours. Found no visible lesions on any of trial patients. "Management is pleased that our BioLexa Platform continues to demonstrate an impressive safety profile during its testing phase," said, Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics. "We believe this therapeutic candidate has the potential to provide significant benefits to people afflicted by Atopic Dermatitis. Going forward, we are focused on expanding our clinical efforts into later stage trials." This stage of the toxicity study was designed to determine dose-limiting adverse events and to define the maximum tolerated dose of the BioLexa Platform. The BioLexa Platform is a proprietary, patented therapeutic designed for the treatment of atopic dermatitis. Over +90% In Upside Potential From Today's Alert Price Diamond Equity Research Initiates Coverage on Hoth Therapeutics, Inc. Slaps on $8.00 Price Target The full research report is available here. Highlights from the report include: Large Market Opportunity Awareness of skin disorders has grown exponentially in recent decades, driving demand for more effective treatments. Eczema is one of the most prevalent skin diseases, with atopic dermatitis (AD) being the most common type affecting a significant portion of the global population. The National Eczema Association estimates conservatively that 31.6 million individuals in the U.S. suffer from eczema, incurring an annual economic burden of around $5.3 billion. The study anticipates that the AD drug sales in the U.S. will grow to $13.6 billion by 2027, which indicates a significant potential market for effective AD treatments. HOTH’s lead product, BioLexa offers a novel potential therapy to treat AD (eczema). It expects to commence a phase 2 trial with enrollment starting in Australia in the end of 2019, with the company targeting a data readout in 1H 2020. The company expects to file the new drug application from mid- to late 2021, which means HOTH could potentially launch its lead product in the U.S. market in 2023. Although HOTH’s investment and timeline in getting its drugs to market are relatively small compared to traditional drug development, HOTH’s pipeline is still earlier stage. We believe HOTH is well positioned to provide investors a unique, high risk high reward small-cap specialty pharma investment opportunity, with its multiple differentiated potential treatments under development. Unique Atopic Dermatitis Treatment Approach HOTH is an early-clinical-stage biopharmaceutical company developing its lead product BioLexa, a unique potential targeted treatment for mild to moderate atopic dermatitis (AD; also known as eczema). BioLexa is one of the first drug candidates to prevent symptoms triggering eczema rather than simply treating symptoms after they occur. It is differentiated as it combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms; in simpler terms, it targets the bacteria as opposed to other eczema treatments addressing the immune-related and inflammatory factors. Hoth uses approved drugs that would enable it to take the faster 505 (b) (2) route for regulatory approval of BioLexa, if the upcoming clinical studies indicate positive results.The company also working with the George Washington University to counter the dermatological-related side effects of Erlotinib therapy in cancer patients, and is developing VNLG 152 with strong preclinical data in the fields of cancer and dermatology. HOTH has established relationships with renowned doctors and scientists and top medical institutions. It recently signed an exclusive licensing agreement with the University of Cincinnati to obtain a patented new food allergy genetic marker; started a pilot study on diabetic skin disorders with the Massachusetts General Hospital’s Vaccine and Immunology Center; expanded its working relationship and signed an exclusive licensing agreement with George Washington University; and entered into a commercial licensing agreement with the University of Maryland (Baltimore) and Isoprene Pharmaceuticals Inc. We anticipate further licensing agreements and collaborations going forward. Competition The global dermatitis drugs market continues to expand, driven by the advancements in numerous drug classes. The AD therapeutics market currently uses conventional forms of therapy such as topical corticosteroids, calcineurin inhibitors, and PDE4 inhibitors to treat patients with mild to moderate AD symptoms.HOTH expects to face significant competition from other current treatments and the development pipelines of large pharmaceutical companies and emerging biotechnology companies. That said, we believe HOTH is well positioned in the industry, with its (1) novel and differentiated potential treatment targeted at preventing the formation of bacterial biofilm and addressing the potential impairment of skin barrier function, (2) patented BioLexa Platform, which combines two existing approved drugs, enabling reliance on existing safety data for those drugs, which could result in faster regulatory approval, (3) strong intellectual property portfolio, including exclusive licenses to patents and trademarks, and (4) additional potential therapies targeting dermatological issues and genetic disorders, including diabetic ulcers, skin aesthetics, psoriasis, and food allergies. Attractive Valuation It is very difficult to value Hoth Therapeutics, Inc. given its early stage and the limited number of similar publicly traded dermatology companies. In our comparable company analysis, we screened for small-capitalization companies in the biopharmaceutical industry focused on developing therapeutics for eczema. We used a blend of these companies to arrive at a mean technology value. We also built a discounted cash flow to value HOTH. From our blended valuation models, we found the shares to be undervalued with significant upside from current trading levels. Based on an average of the two methods, we computed a blended valuation of $8 per share, indicating the stock is undervalued relative to current prices. Market Outlook: More than $320 billion was spent on prescription drugs in the U.S. in 2016, a figure that's expected to nearly double to $610 billion by 2021, according to IQVIA (formerly QuintilesIMS). With so much money being spent on necessary medicines, there's serious opportunity for pharmaceutical companies and investors alike. Atopic dermatitis market predicted to grow $7.2B in 2017 to $24B by end of 2027. It affects more than 32 million patients in the US. Diabetic Foot Ulcers affect approximately 9.1-26.1M people worldwide, about 19 34% of people with diabetes are likely to be affected. Nearly 7.5 million people are affected by psoriasis in the US alone and represent about 2% of the population with approximately 100,000 new cases reported each year.* 60 million people suffering from all grades of acne in the US, 20% of which is severe enough to result in facial scarring. Technical Analysis As we stated above, with HOTH's tiny 4.16M float, any type of market friendly news could send its shares soaring. HOTH has plenty of room to the upside, a move back to its 52-week high of $13.88 would net traders over +230% in profit from today's alert price. We've done our very own chart analysis, and see the potential for a move of over +18% from here. Bullish divergence is forming. HOTH has established strong support at these levels. We've watch HOTH make several strong bounces off support in the past. The Bottom-Line We love these low-float bio-tech alerts. They have the tendency to breakout faster and bigger than any other sector. HOTH's management team possesses a wealth of experience, and we believe that they are the right group of individuals to get this game-changer in the pharma space on the right path towards FDA approval (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, *Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $20,000 cash for a 2-day marketing contract for HOTH. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
NASDAQ:HOTHLong
by RedHotStocks
1
HOTH delivers +13% in profits so far & could jump past $8 today!===================== HOTH (Hoth Therapeutics, Inc.) Float: 3.86M Current Price: $6.80 Low: $6.75 High: $7.90 Realistic Gains/Loss: +13.18% Target Price: $10.00 Chart Analysis Investor Presentation Website | Recent News ======================== Members, Yesterday's low-float Nasdaq listed alert HOTH (Hoth Therapeutics, Inc.) started the day off hot, delivering up +13.18% in realistic profit. It then appeared that some profit taking took place, and shares pulled back to their day low of $6.70. HOTH appeared to form a base at those levels and bounced back in the afternoon, nearly closing in the green on heavy volume. We are banking that this afternoon's momentum will continue on into tomorrow's session. Especially considering the fact that we don't believe the Street got the full effect of yesterday's news release. This morning HOTH dropped huge news regarding its positive steps towards getting FDA approval for their game changing treatment for eczema, BioFlexa. Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution NEW YORK, June 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, today announced the formation of its subsidiary, Hoth Therapeutics Australia Pty Ltd, in anticipation to perform clinical trials for atopic dermatitis. Hoth Therapeutics Australia Pty Ltd will oversee the preparation and execution of Hoth's first clinical trial, known as Efficacy and Safety of BioLexa for the Treatment of Mild-to-Moderate Atopic Dermatitis. The newly formed entity will also be eligible for a significant Research and Development tax rebate. The subsidiary will supervise data management, biostatistical, medical monitoring, quality insurance, regulatory and central laboratory services to support the trial. "We are excited by the opportunity to work with Australian researchers and members of the international pharmaceutical industry, in regards to the development of our proprietary atopic dermatitis treatment," stated Mr. Robb Knie, CEO of Hoth Therapeutics. "This endeavor is a significant milestone for us, as we move towards clinical trials. Hoth is committed to working diligently with physicians, and regulators in order to successfully pilot our BioLexa Platform to the millions of people that are afflicted with atopic dermatitis." The subsidiary was formed in connection with Novotech and CoSec Consulting. Headquartered in Australia since 1996 and operating in the Asia Pacific region, Novotech is internationally recognized in the industry as a leading regional full-service contract research organization. Cosec Consulting provides carefully crafted compliance, governance and financial solutions for offshore companies undertaking research and development activities in Australia. This market friendly news sent shares soaring this morning, but we can only imagine the type of move it will make once it has more eyes on it. We also noticed that the Level II on this low-float biotech play is extremely thin, and we are anticipating a possible move past $8.00 when all is said and done. We witnessed some wild swings between $6 and $7 yesterday, with a little more volume HOTH could easily run past $8. Remember... HOTH is the perfect candidate for a monster breakout. The Company: Has a tight float of 3.86M Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News) Is listed on the Nasdaq Exchange (High Liquidity) Has a $10 Price Target (+52% Upside) HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88. HOTH's recent pullback has created the ultimate buy the dip opportunity for traders. We all know how explosive these small-cap biotech stocks can be... Any type of market friendly news could trigger a huge move in share price. On Wednesday we watched RWLK jump over +200% on positive FDA news. With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring. HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach. Atopic Dermatitis is a large and growing market Affects more than 32 million patients in the US 10 20% of all pediatric patients suffer from Atopic Dermatitis Need for new, differentiated therapies HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019 Study will test efficacy, safety, and ease of use On target to complete Phase 2 clinical trial by end of Q1 2020 As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline. Can you imagine how high HOTH shares could go if it were to receive FDA approval? Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains. The Bottom-Line We love these low-float bio-tech alerts. They have the tendency to breakout faster and bigger than any other sector. This is the only ticker that should be on your radar today. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Click here to view our full profile on HOTH. Best Regards, The TopMarketGainers Team Don't Miss Our Next Huge Winner... Text 'GAINS' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
NASDAQ:HOTHLong
by RedHotStocks
1
$HOTH is our low-float Nasdaq listed biotech Breakout alert $10===================== HOTH (Hoth Therapeutics, Inc.) Float: 3.86M Alert Price: $6.57 Target Price: $10.00 Chart Analysis Investor Presentation Website | Recent News ======================== Members, We hope you enjoyed the easy double-digit gains that today's trade idea delivered. You'll be happy to know that we have already identified an even more exciting trade idea for you. Please turn your immediate attention to HOTH (Hoth Therapeutics, Inc.) HOTH is the perfect candidate for a monster move tomorrow. The Company: Has a tight float of 3.86M Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News) Is listed on the Nasdaq Exchange (High Liquidity) Suffered a sharp pullback today (Perfect "Buy the Dip" Opportunity") Has a $10 Price Target (+52% Upside) HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88. HOTH's recent pullback has created the ultimate buy the dip opportunity for traders. We all know how explosive these small-cap biotech stocks can be... Any type of market friendly news could trigger a huge move in share price. Today we watched RWLK jump over +200% on positive FDA news. With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring. HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach. Atopic Dermatitis is a large and growing market Affects more than 32 million patients in the US 10 20% of all pediatric patients suffer from Atopic Dermatitis Need for new, differentiated therapies HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019 Study will test efficacy, safety, and ease of use On target to complete Phase 2 clinical trial by end of Q1 2020 As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline. Can you imagine how high HOTH shares could go if it were to receive FDA approval? Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains. About HOTH Therapeutics Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform. Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur. They intend to explore the use of the BioLexa™ Platform for the treatment of atopic dermatitis, or eczema. They also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. They believe that the BioLexa Platform™s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection. Finally, they intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform™s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus. Genetic Marker License Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology. Company Highlights: Unique small cap specialty pharma investment opportunity with multiple shots on goal and capital business model. Multi-billion market opportunity with large unmet need for both the Company’s primary and secondary asset. Proprietary platform technology which combines two existing approved drugs enabling reliance on existing safety data for those drugs. Proprietary BioLexa platform technology which combines two existing approved drugs enabling reliance on existing safety data. VNLG 152 strong pre-clinical data in acne and psoriasis. Strong IP Portfolio, including licenses to patents and trademarks. Signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin. Experienced management team, board of directors and scientific advisors with proven drug development experience. Recent Milestones Entered into licensing agreement with the University of Maryland and Isoprene Pharmaceuticals. (March 2019) Began pilot study in chronic diabetic ulcers at Mass General Vaccine and Immunotherapy Center (March 2019) Announced Closing of Initial Public Offering. Latest News Hoth and Zylö to use new topical application of an endocannabinoid, anandamide (AEA), in nanoparticles NEW YORK , May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin. Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; www.zylotherapeutics.com Scientists at Einstein College of Medicine recently demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. This work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases. The work at Einstein supports the thesis that AEA loaded into Z-pods™ improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation. According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month. "Management is extremely pleased to partner with Zylö Therapeutics, enhancing our portfolio of unique treatments for patients suffering from various dermatological related ailments," stated, Mr. Robb Knie, CEO of Hoth Therapeutics. "Zylö's initial work shows significant promise in combating Cutaneous Lupus Erythematosus, and we look forward to working with them in order to bring this treatment to market." "We are thrilled to partner with Hoth, a company that is committed to innovative solutions and partnerships to develop treatments for diseases with a high unmet clinical need, such as lupus," said Scott Pancoast, CEO of Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods through the next stages of development, we expect to further demonstrate the important role that our patented Z-pod delivery system plays in improving treatment outcomes." The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all. Market Outlook: Atopic dermatitis market predicted to grow $7.2B in 2017 to $24B by end of 2027. It affects more than 32 million patients in the US. Diabetic Foot Ulcers affect approximately 9.1-26.1M people worldwide, about 19 34% of people with diabetes are likely to be affected. Nearly 7.5 million people are affected by psoriasis in the US alone and represent about 2% of the population with approximately 100,000 new cases reported each year.* 60 million people suffering from all grades of acne in the US, 20% of which is severe enough to result in facial scarring. Technical Analysis As we stated above, with HOTH's tiny 3.2M float, any type of market friendly news could send its shares soaring. HOTH suffered a sharp pullback today creating the perfect "Buy the Dip" opportunity. HOTH has plenty of room to the upside, a move back to its 52-week high of $13.88 would net traders over +100% in profit from today's alert price. We've done our very own chart analysis and see the potential for a move to $13.82. HOTH has shown very little resistance once it breaks $8.80. We see a strong uptrend, and an impulse to move higher. This is a potential triple-digit gain opportunity The Bottom-Line We love these low-float bio-tech alerts. They have the tendency to breakout faster and bigger than any other sector. HOTH has the potential to be the next RWLK , and could lead the NASDAQ in gains tomorrow. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, The PennyStock101 Team Don't Miss Our Next Huge Winner... Text 'PS101' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
NASDAQ:HOTHLong
by DEXWireNews
$HOTH is our low-float Nasdaq listed biotech Breakout alert $10 ===================== HOTH (Hoth Therapeutics, Inc.) Float: 3.86M Alert Price: $6.57 Target Price: $10.00 Chart Analysis Investor Presentation Website | Recent News ======================== Members, We hope you enjoyed the easy double-digit gains that today's trade idea delivered. You'll be happy to know that we have already identified an even more exciting trade idea for you. Please turn your immediate attention to HOTH (Hoth Therapeutics, Inc.) HOTH is the perfect candidate for a monster move tomorrow. The Company: Has a tight float of 3.86M Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News) Is listed on the Nasdaq Exchange (High Liquidity) Suffered a sharp pullback today (Perfect "Buy the Dip" Opportunity") Has a $10 Price Target (+52% Upside) HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88. HOTH's recent pullback has created the ultimate buy the dip opportunity for traders. We all know how explosive these small-cap biotech stocks can be... Any type of market friendly news could trigger a huge move in share price. Today we watched RWLK jump over +200% on positive FDA news. With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring. HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach. Atopic Dermatitis is a large and growing market Affects more than 32 million patients in the US 10 20% of all pediatric patients suffer from Atopic Dermatitis Need for new, differentiated therapies HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019 Study will test efficacy, safety, and ease of use On target to complete Phase 2 clinical trial by end of Q1 2020 As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline. Can you imagine how high HOTH shares could go if it were to receive FDA approval? Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains. About HOTH Therapeutics Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform. Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur. They intend to explore the use of the BioLexa™ Platform for the treatment of atopic dermatitis, or eczema. They also intend to explore the use of the BioLexa Platform™ in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures. They believe that the BioLexa Platform™s ability to fight bacterial growth will enable the innate immune system to focus on optimal healing rather than fighting post-procedure infection. Finally, they intend to explore the use of the BioLexa Platform™ in connection with diabetic foot ulcers. We believe that the BioLexa Platform™s ability to fight bacterial growth will help initiate and/or improve chronic diabetic wound healing as well as accelerate the healing of diabetic wounds with S. aureus. Genetic Marker License Hoth has also licensed exclusive rights to certain patented technology from the University of Cincinnati for use in determining the risk that a patient will develop allergies to peanuts, milk and other foods as well as predict propensity for eczema. Hoth’s overall goal is to develop and make ready for commercialization a family of genetic screening tests based on the licensed technology. Company Highlights: Unique small cap specialty pharma investment opportunity with multiple shots on goal and capital business model. Multi-billion market opportunity with large unmet need for both the Company’s primary and secondary asset. Proprietary platform technology which combines two existing approved drugs enabling reliance on existing safety data for those drugs. Proprietary BioLexa platform technology which combines two existing approved drugs enabling reliance on existing safety data. VNLG 152 strong pre-clinical data in acne and psoriasis. Strong IP Portfolio, including licenses to patents and trademarks. Signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin. Experienced management team, board of directors and scientific advisors with proven drug development experience. Recent Milestones Entered into licensing agreement with the University of Maryland and Isoprene Pharmaceuticals. (March 2019) Began pilot study in chronic diabetic ulcers at Mass General Vaccine and Immunotherapy Center (March 2019) Announced Closing of Initial Public Offering. Latest News Hoth and Zylö to use new topical application of an endocannabinoid, anandamide (AEA), in nanoparticles NEW YORK, May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin. Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; www.zylotherapeutics.com Scientists at Einstein College of Medicine recently demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. This work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases. The work at Einstein supports the thesis that AEA loaded into Z-pods™ improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation. According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month. "Management is extremely pleased to partner with Zylö Therapeutics, enhancing our portfolio of unique treatments for patients suffering from various dermatological related ailments," stated, Mr. Robb Knie, CEO of Hoth Therapeutics. "Zylö's initial work shows significant promise in combating Cutaneous Lupus Erythematosus, and we look forward to working with them in order to bring this treatment to market." "We are thrilled to partner with Hoth, a company that is committed to innovative solutions and partnerships to develop treatments for diseases with a high unmet clinical need, such as lupus," said Scott Pancoast, CEO of Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods through the next stages of development, we expect to further demonstrate the important role that our patented Z-pod delivery system plays in improving treatment outcomes." The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all. Market Outlook: Atopic dermatitis market predicted to grow $7.2B in 2017 to $24B by end of 2027. It affects more than 32 million patients in the US. Diabetic Foot Ulcers affect approximately 9.1-26.1M people worldwide, about 19 34% of people with diabetes are likely to be affected. Nearly 7.5 million people are affected by psoriasis in the US alone and represent about 2% of the population with approximately 100,000 new cases reported each year.* 60 million people suffering from all grades of acne in the US, 20% of which is severe enough to result in facial scarring. Technical Analysis As we stated above, with HOTH's tiny 3.2M float, any type of market friendly news could send its shares soaring. HOTH suffered a sharp pullback today creating the perfect "Buy the Dip" opportunity. HOTH has plenty of room to the upside, a move back to its 52-week high of $13.88 would net traders over +100% in profit from today's alert price. We've done our very own chart analysis and see the potential for a move to $13.82. HOTH has shown very little resistance once it breaks $8.80. We see a strong uptrend, and an impulse to move higher. This is a potential triple-digit gain opportunity The Bottom-Line We love these low-float bio-tech alerts. They have the tendency to breakout faster and bigger than any other sector. HOTH has the potential to be the next RWLK, and could lead the NASDAQ in gains tomorrow. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, The PennyStock101 Team Don't Miss Our Next Huge Winner... Text 'PS101' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
NASDAQ:HOTHLong
by RedHotStocks